Medical Crossfire®: ADCs and Bispecifics in Lung Cancer—Hype, Hope, or a New Standard of Care?

Activity Overview

Antibody-drug conjugates (ADCs) and bispecific antibodies are rapidly changing the treatment landscape in thoracic oncology. In non-small cell lung cancer (NSCLC), several ADCs and bispecific antibodies are already reshaping established treatment paradigms. In small cell lung cancer (SCLC), novel bispecific T-cell engagers and ADCs are driving meaningful advances in a historically limited therapeutic landscape. As these drug classes expand across lines of therapy, clinicians face increasing complexity in treatment selection, sequencing, toxicity management, and biomarker-driven decision-making.

The Medical Crossfire® format is uniquely suited to closing these gaps, bringing together leading thoracic oncology experts at the point where practice-changing data emerges. Its structured debate format allows expert disagreement to surface—and be resolved—in real time, giving physicians greater confidence to implement these cutting-edge therapies in their practice.

This program was approved by the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer Program and Education Committees as an independent activity held in conjunction with the IASLC 2026 World Conference on Lung Cancer.

This program is not sponsored or endorsed by IASLC and is not part of the official IASLC-accredited program.

This educational activity is an archive of the live virtual symposium held on September 12, 2026.

Target Audience

This educational activity is directed toward oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers involved in the management of lung cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Identify the molecular targets and mechanisms of action of individual ADCs and bispecific antibodies relevant to the treatment of NSCLC and SCLC
• Evaluate clinical trial data for approved and investigational ADCs and bispecifics in lung cancer
• Develop individualized treatment strategies for patients with lung cancer, incorporating ADCs and bispecifics, accounting for patient-specific factors, biomarker status, and sequencing implications

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners before the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.